Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial - PubMed (original) (raw)

Clinical Trial

. 2010 Jul;16(7):1005-17.

doi: 10.1016/j.bbmt.2010.02.009. Epub 2010 Feb 16.

Robert J Soiffer, Joseph H Antin, Hajime Uno, Zhezhen Jin, Joanne Kurtzberg, Paul L Martin, Gideon Steinbach, Karen F Murray, Georgia B Vogelsang, Allen R Chen, Amrita Krishnan, Nancy A Kernan, David E Avigan, Thomas R Spitzer, Howard M Shulman, Donald N Di Salvo, Carolyn Revta, Diane Warren, Parisa Momtaz, Gary Bradwin, L J Wei, Massimo Iacobelli, George B McDonald, Eva C Guinan

Affiliations

Clinical Trial

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial

Paul G Richardson et al. Biol Blood Marrow Transplant. 2010 Jul.

Abstract

Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal, but early phase I/II studies have suggested promising activity and acceptable toxicity using the novel polydisperse oligonucleotide defibrotide. This randomized phase II dose-finding trial determined the efficacy of defibrotide in patients with severe VOD following hematopoietic stem cell transplantation (HSCT) and identified an appropriate dose for future trials. Adult and pediatric patients received either lower-dose (arm A: 25 mg/kg/day; n = 75) or higher-dose (arm B: 40 mg/kg/day; n = 74) i.v. defibrotide administered in divided doses every 6 hours for > or =14 days or until complete response, VOD progression, or any unacceptable toxicity occurred. Overall complete response and day +100 post-HSCT survival rates were 46% and 42%, respectively, with no significant difference between treatment arms. The incidence of treatment-related adverse events was low (8% overall; 7% in arm A, 10% in arm B); there was no significant difference in the overall rate of adverse events between treatment arms. Early stabilization or decreased bilirubin was associated with better response and day +100 survival, and decreased plasminogen activator inhibitor type 1 (PAI-1) during treatment was associated with better outcome; changes were similar in both treatment arms. Defibrotide 25 or 40 mg/kg/day also appears effective in treating severe VOD following HSCT. In the absence of any differences in activity, toxicity or changes in PAI-1 level, defibrotide 25 mg/kg/day was selected for ongoing phase III trials in VOD.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Disposition of patients. Flowchart illustrating the progression of patients with severe hepatic VOD after HSCT by treatment group (arm A, 25 mg/kg/day i.v. defibrotide; arm B, 40 mg/kg/day i.v. defibrotide).

Figure 2

Figure 2

Survival of patients with severe hepatic VOD by treatment arm post-HSCT (A) and after randomization (B) (treated population). Kaplan-Meier curves show survival distributions for patients in treatment arms A and B.

Figure 3

Figure 3

Survival of patients with severe hepatic VOD by treatment arm for adult patients post-HSCT (A) and after randomization (B) and for pediatric patients post-HSCT (C) and after randomization (D) (treated population). Kaplan-Meier curves show survival distributions for patients aged ≥18 years and aged <18 years.

Figure 4

Figure 4

Mean (standard deviation) PAI-1 (A) and total bilirubin (B) by treatment arm and outcome in patients with severe hepatic VOD treated with i.v. defibrotide. Bar charts illustrate PAI-1 levels (A) and total bilirubin levels (B) by CR/nonresponse, day +100 post-HSCT survival/nonsurvival, and treatment arm. D, day; NR, nonresponder.

References

    1. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001;106:57–68. - PubMed
    1. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–122. - PubMed
    1. Blostein MD, Paltiel OB, Thibault A, et al. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992;10:439–443. - PubMed
    1. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5:306–315. - PubMed
    1. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599–3604. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources